ACE and bone neoplasm: In the current study, SP600125 did not alter tumor growth in the bone but increased the Ace-1-Dkk-1YFP-Luc osteoblastic and osteolytic phenotype of the bone tumors with increased cortical invasion and secondary induction of periosteal new bone formation.